AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

When she first stepped into urgent care in early December, Maggie O'Neil wondered whether her unaccounted-for bruises and fatigue were worth the wait for a clinician. "I thought I had low iron or ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

The following is a summary of “Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...